Dr Luke Tyson Consultant hepatologist
- Patient age group
- Adults
- Consultant registered on
- 20/07/2011
- Primary medical qualifications
- MB BChir
- Gender
- Male
- Services
- Hospitals
Contact
- Phone
- 020 3312 6254
Hepatology admin team, liver unit, St Mary's Hospital
Background
Dr Tyson qualified from the University of Cambridge in 2011. He undertook his higher specialty training in the North West Thames region. As well as his medical degrees, he has completed a PhD with Imperial College London. Dr Tyson has published widely and has won a variety of competitive bursaries and prizes. Dr Tyson is on the Specialist Register for Gastroenterology with a sub-specialty in Hepatology. Currently, Dr Tyson is a Consultant Hepatologist at Imperial College Healthcare NHS Trust. Dr Tyson works cross-trust as a Consultant Gastroenterologist and Hepatologist at Northwick Park and St Mark’s hospitals.
Dr Tyson is interested in all aspects of hepatology, as well as general gastroenterology including irritable bowel syndrome and its mimics. He has a particular interest in steatotic (‘fatty’) liver diseases. Dr Tyson has an active research interest in alcohol-related liver disease, and leads the non-alcoholic fatty liver disease service at Northwick Park and St Mark’s. Dr Tyson is an experienced endoscopist and performs upper and lower gastrointestinal endoscopy (colonoscopy) for a range of gastrointestinal disorders.
Expertise
Hepatology; liver disease; alcohol-related liver disease (ARLD/ ALD); non-alcoholic fatty liver disease (NAFLD); metabolic-associated steatotic liver disease (MASLD); cirrhosis; fibroscan; gastroenterology; upper gastrointestinal endoscopy (OGD); colonoscopy.
Research & publications
In severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAs
Tyson LD, Atkinson S, Hunter RW, Allison M, Austin A, Dear JW, Forrest E, Liu T, Lord E, Masson S, Nunes J, Richardson P, Ryder SD, Wright M, Thursz M, Vergis N. Aliment Pharmacol Ther. 2023 Dec;58(11-12):1217-1229. doi: 10.1111/apt.17733. Epub 2023 Oct 2. PMID: 37781965; PMCID: PMC10946848.
Liver cancer: screening, diagnosis and management
Qurashi M, Vithayathil M, Corrigall D, Tyson LD, Sharma R. The Pharmaceutical J. 02/05/2023; https://pharmaceutical-journal.com/article/ld/liver-cancer-screening-diagnosis-and-management
Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Tyson LD, Cheng A, Kelleher C, Strathie K, Lovendoski J, Habtemariam Z, Lewis H. Eur J Gastroenterol Hepatol. 2022 May 1;34(5):567-575. doi: 10.1097/MEG.0000000000002304. PMID: 35421022.
How I treat… alcohol-related liver disease.
Tyson LD, Lewis H. Clin Med (Lond). 2019 Jan;19(1):43-46. doi: 10.7861/clinmedicine.19-1-43. PMID: 30651244; PMCID: PMC6399631.